Welcome to our dedicated page for Inspire Medical Systems SEC filings (Ticker: INSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Inspire Medical Systems's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Inspire Medical Systems's regulatory disclosures and financial reporting.
Inspire Medical Systems, Inc. (symbol INSP) has a shareholder, John Rondoni, who has filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 64 shares of common stock, with an aggregate market value of $3,991.04, to be sold through Morgan Stanley Smith Barney LLC on or about August 24, 2026 on the NYSE. The shares were acquired under an employee stock purchase plan, and the filing states that the securities to be sold were acquired under the plan on December 31, 2023 and December 31, 2024. The filing also notes that 28,910,375 shares of Inspire Medical Systems common stock are outstanding; this is a baseline figure, not the amount being sold.
Inspire Medical Systems, Inc. has a significant shareholder group led by Soleus Capital Master Fund, L.P. and related entities, which report beneficial ownership of 1,931,436 shares of common stock of the company. This position represents 6.7% of Inspire’s common stock, based on 28,910,375 shares outstanding as of July 30, 2026 as reported in Inspire’s Form 10-Q for the quarter ended June 30, 2026.
The Soleus entities and Guy Levy report shared voting and dispositive power over 1,931,436 shares and no sole voting or dispositive power. They state that the shares are held directly by Soleus Capital Master Fund, L.P. and that each affiliated entity and Mr. Levy disclaims beneficial ownership of these shares except for purposes of determining obligations under Section 13(d) of the Exchange Act.
AQR Capital Management, LLC and its parent AQR Capital Management Holdings, LLC report beneficial ownership of common stock of Inspire Medical Systems, Inc.
The AQR entities collectively beneficially own 1,856,800 shares of Inspire Medical Systems common stock, representing 6.44% of the class. They report shared voting power over 1,783,224 shares and shared dispositive power over 1,856,800 shares, with no sole voting or dispositive power. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC.
Inspire Medical Systems, Inc. insider Jason P. Kelly, Chief Manufacturing and Quality Officer, reported a sale of 963 shares of common stock on 2026-08-07 at $59.55 per share. Following this open-market sale, Kelly directly holds 18,985 shares of Inspire Medical Systems common stock.
Inspire Medical Systems, Inc. reported that Chief People Officer Melissa Mann had shares of common stock withheld to satisfy tax obligations upon vesting of RSUs granted on July 31, 2024.
Two tax-withholding dispositions each covered 326 shares at $50.21 on July 31, 2026 and $124.54 on July 31, 2025.
Inspire Medical Systems reported Q2 2026 results with revenue of $200.6 million, down 7.6% from Q2 2025, mainly from U.S. coding and reimbursement pressures, partly offset by international growth. Gross margin improved to 85.5%, operating expenses fell 7.4% to $172.0 million, and net earnings were $0.3 million, or diluted EPS of $0.01; adjusted diluted EPS was $0.14.
Operating cash flow rose to $23.2 million from $2.7 million, and cash, cash equivalents, and investments increased to $415.2 million as of June 30, 2026. For 2026, the company now guides revenue to $835–$875 million, adjusted operating margin of 4–6%, and adjusted EPS of $1.05–$1.45. It also launched Project Horizon, a strategic growth plan expected to incur $20–$25 million of pre-tax restructuring charges and to create about $30 million of annualized investment capacity for revenue growth initiatives, with most actions targeted for completion by Q3 2026 and substantially complete by year-end.
Vanguard Portfolio Management LLC filed an amended Schedule 13G reporting beneficial ownership of common stock of Inspire Medical Systems Inc. Vanguard reports beneficial ownership of 2,126,116 shares, representing 7.37% of the outstanding common stock.
Vanguard has sole voting power over 37,155 shares and sole dispositive power over all 2,126,116 shares, with no shared voting or dispositive power. The filing notes that these securities are held across Vanguard funds and other managed accounts for which Vanguard and certain affiliates exercise voting and/or dispositive power, and that no other single person has an interest in more than 5% of the class through these holdings.
BlackRock, Inc. filed an amended ownership report stating that its reporting business units beneficially own 4,163,016 shares of Inspire Medical Systems, Inc. common stock, representing 14.4% of the outstanding class as of June 30, 2026.
BlackRock reports sole voting power over 4,116,712 shares and sole dispositive power over all 4,163,016 shares, with no shared voting or dispositive power. The filing notes that iShares Core S&P Small-Cap ETF has an interest in more than five percent of Inspire Medical Systems’ common stock. The disclosure aggregates certain BlackRock business units and excludes others that report ownership separately.